APA (7th ed.) Citation

Richardson, D. L., Moore, K. N., Vergote, I., Gilbert, L., Martin, L. P., Mantia-Smaldone, G. M., . . . O'Malley, D. M. (2024). Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecologic Oncology, 185, 186. https://doi.org/10.1016/j.ygyno.2024.01.045

Chicago Style (17th ed.) Citation

Richardson, Debra L., et al. "Phase 1b Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)–targeting Antibody-drug Conjugate, in Combination with Carboplatin and Bevacizumab in Patients with Platinum-sensitive Ovarian Cancer." Gynecologic Oncology 185 (2024): 186. https://doi.org/10.1016/j.ygyno.2024.01.045.

MLA (9th ed.) Citation

Richardson, Debra L., et al. "Phase 1b Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)–targeting Antibody-drug Conjugate, in Combination with Carboplatin and Bevacizumab in Patients with Platinum-sensitive Ovarian Cancer." Gynecologic Oncology, vol. 185, 2024, p. 186, https://doi.org/10.1016/j.ygyno.2024.01.045.